AI good for human health and that of global data science

Hoping to encourage interdisciplinary collaboration around Big Data over the next 50 to 100 years, Boston University is preparing to build a 17-story architectural marvel.

The school’s formidable news division has been covering the development in a series of articles. The latest looks at BU’s work with AI in healthcare.

For the piece, writer Art Jahnke spoke with scholars in medicine, pharmacology, global health, neurosurgery and other disciplines—not least data science.

For example, he describes the work of a data scientist who’s working with a systems engineer to help identify patients at risk of heart disease or diabetes. Their project will involve training algorithms on health data from EHRs as well as from wearable, implantable and home-based networked diagnostic devices.

“Eventually, we hope to move from predictions to prescriptions,” data scientist Yannis Paschalidis, PhD, tells the reporter. “We have some initial results for diabetes and hypertension. The goal is to make recommendations available in electronic health records as guidance for the care provider.”

Jahnke also introduces a professor of global health who’s working with a colleague in computer science to better understand Western influences on dietary trends in Kenya. The project has them analyzing millions of Instagram images posted by people living in the East African country.

Once they train their algorithm to recognize African foods, they’ll work to figure out “how ‘green’ or how ‘greasy’ the Kenyan diet is, and if it varies in urban and rural areas.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup